Scientists to test if blocking the psychedelic 'Trip' kills the benefits
NCT ID NCT06768944
First seen Jan 08, 2026 · Last updated May 10, 2026 · Updated 17 times
Summary
This study looks at whether the intense, subjective experience (the 'trip') caused by psilocybin, the active ingredient in magic mushrooms, is necessary for its positive after-effects. Researchers will give 128 healthy adults psilocybin along with either a placebo or risperidone, a drug that blocks the psychedelic effects. By comparing the two groups, they hope to understand if the subjective experience itself is key to any lasting positive changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVESTIGATING THE IMPORTANCE OF THE SUBJECTIVE PSYCHEDELIC EXPERIENCE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Calgary
Calgary, Alberta, T2N 4N1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.